|
AlloVir, Inc. (ALVR) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
AlloVir, Inc. (ALVR) Bundle
Optimize your time and improve precision with our (ALVR) DCF Calculator! Utilizing up-to-date AlloVir data and customizable assumptions, this tool allows you to forecast, analyze, and value AlloVir, Inc. like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -69.7 | -169.8 | -166.4 | -190.1 | -65.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | 1.1 | 2.6 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -69.8 | -171.0 | -169.0 | -190.5 | -65.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 356.3 | 248.1 | 233.8 | 183.9 | 118.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .5 | .1 | .2 | .2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -.5 | -.1 | -.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.0 | 8.4 | 3.0 | 6.8 | .2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -68.4 | -172.0 | -168.7 | -190.4 | -65.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -67.6 | -163.5 | -171.4 | -186.5 | -71.7 | -.2 | .0 | .0 | .0 | .0 |
| WACC, % | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -118 | |||||||||
| Equity Value | 118 | |||||||||
| Diluted Shares Outstanding, MM | 5,008 | |||||||||
| Equity Value Per Share | 0.02 |
What You Will Get
- Real AlloVir Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for AlloVir, Inc. (ALVR).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to AlloVir, Inc. (ALVR).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on AlloVir, Inc.'s (ALVR) fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for AlloVir, Inc. (ALVR).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for AlloVir, Inc. (ALVR).
Key Features
- 🔍 Real-Life ALVR Financials: Pre-filled historical and projected data for AlloVir, Inc. (ALVR).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate AlloVir’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize AlloVir’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Get the pre-built Excel file containing AlloVir, Inc.'s (ALVR) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for AlloVir, Inc. (ALVR)?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses all in one solution.
- Customizable Inputs: Modify the yellow-highlighted cells to explore different scenarios.
- Detailed Insights: Automatically computes AlloVir’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points.
- Professional Quality: Perfect for financial analysts, investors, and business consultants.
Who Should Use AlloVir, Inc. (ALVR)?
- Investors: Gain insights into cutting-edge therapies and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to evaluate the potential of innovative treatments.
- Consultants: Tailor presentations or reports swiftly using AlloVir's latest research and developments.
- Biotech Enthusiasts: Enhance your knowledge of viral therapies and their market implications through real-world case studies.
- Educators and Students: Leverage AlloVir's resources as a practical tool in biotechnology and healthcare courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled AlloVir, Inc. (ALVR) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for AlloVir, Inc. (ALVR).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.